Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing novel cardiovascular medicines. Its lead commercial product is CARDAMYST (etripamil) nasal spray, a self-administered, rapid-onset calcium channel blocker designed to convert acute symptomatic attacks of paroxysmal supraventricular tachycardia (PSVT) into normal sinus rhythm. In addition to commercializing CARDAMYST, the company develops etripamil to manage acute ventricular rates in patients suffering from atrial fibrillation with rapid ventricular rate (AFib-RVR). Its target customers comprise healthcare providers—predominantly clinical cardiologists, interventional cardiologists, electrophysiologists, and select primary care physicians—who treat adult patients with these episodic cardiac arrhythmias, with products supplied via third-party logistics to drug wholesalers and retail pharmacies.

The company markets its treatment in the United States using a dedicated specialty sales team of roughly 60 representatives who call on thousands of prescribers. Internationally, the company pursues commercialization and regulatory approvals through regional partnerships, including marketing authorization applications submitted in the European Union and China. Milestone Pharmaceuticals operates without internal manufacturing facilities, relying entirely on a global contract supply chain for drug substance production, device formulation, assembly, and packaging. The provided excerpt does not disclose the location of the company's headquarters.

Summary of the business section of Milestone Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 38 full-time employees, 13 of whom were primarily engaged in research and development activities.”